^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RBPMS-MET fusion

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase, RBPMS, RNA-binding protein with multiple splicing, Heart and RRM expressed sequence, HERMES, RBP-MS
    Entrez ID:
    4233; 11030
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    8d
    Precision medicine: an intrahepatic cholangiocarcinoma with a novel RBPMS-MET fusion sensitive to crizotinib. (PubMed, Oncologist)
    Our case report strengthens the evidence that crizotinib may be a viable treatment option for patients with ICC with a c-MET tyrosine kinase fusion, necessitating additional clinical investigation.
    Journal • PD(L)-1 Biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • RBPMS (RNA-binding protein with multiple splicing) • CA 19-9 (Cancer antigen 19-9)
    |
    MET fusion • RBPMS-MET fusion
    |
    Keytruda (pembrolizumab) • Xalkori (crizotinib) • gemcitabine • Lenvima (lenvatinib) • capecitabine